On September 3, 2025, Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has entered into convertible note subscription agreements with SurgCenter principals, Gregory George, and William Gueck, who are also existing Mesoblast shareholders. These agreements allow Mesoblast to issue up to US$50.0 million (A$76.8 million) of unsecured convertible notes. The funding, subject to shareholder approval, can be used to repay or reduce the amount owed to secured lenders under existing loan agreements, as well as for general working capital purposes.